BioAtla (BCAB) Income towards Parent Company (2020 - 2026)
BioAtla's (BCAB) quarterly Income towards Parent Company came in at -$9.3 million in Q1 2026, up 46.91% year-on-year from -$6.3 million in Q1 2025, and down 1.19% quarter-over-quarter from -$9.2 million in Q4 2025.
BioAtla (BCAB) Income towards Parent Company (2020 - 2026) Analysis & Trends
BioAtla's Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 46.91% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$60.0 million, a 11.48% increase from a year earlier, with the FY2025 full-year figure at -$174.4 million, down 0.67% from the prior year.
- Income towards Parent Company retreated to -$9.3 million in Q1 2026 per BCAB's latest filing, from -$9.2 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$9.2 million in Q4 2025 and bottomed at -$2.8 billion in Q3 2022.
- The 5-year median for Income towards Parent Company is -$26.3 million (2025), against an average of -$219.2 million.
- Across the five-year window, Income towards Parent Company slumped 11403.2% in 2022 and soared 98.76% in 2023, its largest moves.
- Year by year, Income towards Parent Company stood at -$27.9 million in 2022, then increased by 2.65% to -$27.2 million in 2023, then jumped by 42.24% to -$15.7 million in 2024, then soared by 41.5% to -$9.2 million in 2025, then declined by 1.19% to -$9.3 million in 2026.
- Per Business Quant, the three latest BCAB Income towards Parent Company figures stand at -$9.3 million (Q1 2026), -$9.2 million (Q4 2025), and -$15.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | BioAtla | 5.08 Mn | 5.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.29 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -15.28 Mn |
| Jun 30, 2025 | -26.27 Mn |
| Mar 31, 2025 | -17.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -11.85 Mn |
| Jun 30, 2024 | -22.77 Mn |
| Mar 31, 2024 | -472.87 Mn |
| Dec 31, 2023 | -27.17 Mn |
| Sep 30, 2023 | -34.13 Mn |
| Jun 30, 2023 | -133.99 Mn |
| Mar 31, 2023 | -27.86 Mn |
| Dec 31, 2022 | -27.91 Mn |
| Sep 30, 2022 | -2.76 Bn |
| Jun 30, 2022 | -91.08 Mn |
| Mar 31, 2022 | -24.64 Mn |
| Dec 31, 2021 | -23.76 Mn |
| Sep 30, 2021 | -23.99 Mn |
| Jun 30, 2021 | -45.58 Mn |